Revamped MCAC to review ICDs
This article was originally published in The Gray Sheet
Executive Summary
Medicare Coverage Advisory Committee will convene Feb. 12 at the Baltimore Convention Center to evaluate "all indications for ICDs," responding to Guidant's request that CMS cover prophylactic implantation of the devices. The meeting will be the first under 1MCAC's revised charter abandoning the use of specialty panels in favor of floating members. The event will feature 15 committee members, with a chair and vice-chair still to be announced. Future meeting participants will be selected from a maximum pool of 100 members, based on expertise and availability. Comments on the ICD meeting are due Jan. 29. With the MCAC Executive Committee step eliminated, CMS estimates it will take roughly 90 days after the meeting to issue a decision memo...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.